New Zealand GPs Begin Issuing First Adult ADHD Prescriptions Following Policy Shift

Historic Policy Change Takes Effect

As of February 1, 2026, general practitioners (GPs) and nurse practitioners (NPs) in New Zealand are now able to diagnose Attention-Deficit Hyperactivity Disorder (ADHD) in adults aged 18 and over and initiate prescriptions for stimulant medications. This marks a substantial shift from previous regulations, which required a recommendation from a psychiatrist or paediatrician for initial prescribing. The change is expected to significantly enhance access to treatment for many New Zealanders who have faced considerable hurdles in obtaining a diagnosis and ongoing care.

Addressing Access Barriers and Costs

The regulatory amendments, a result of consultations by Pharmac and Medsafe, were welcomed by Minister for Mental Health Matt Doocey, who stated that the decision would provide New Zealanders with 'faster access to assessments and treatment'. Previously, individuals seeking an ADHD diagnosis and medication often encountered lengthy wait times and substantial costs associated with specialist appointments. The new framework allows vocationally trained GPs and NPs with a specific interest in ADHD to assess, diagnose, and treat adult patients, thereby extending the scope of primary care.

One of the first patients to benefit from the new system, Adam Currie, described his experience as 'really smooth', noting that the medication had been 'life-changing' for him. The stimulant medications now prescribable by GPs and NPs include methylphenidate (e.g., Ritalin, Concerta) and dexamfetamine (e.g., Vyvanse).

Implementation and Future Considerations

While the changes are largely seen as a positive step, particularly by advocacy groups such as Aroreretini Aotearoa and ADHD New Zealand, some challenges and considerations remain. It is anticipated that not all general practices will immediately offer these services, and the rollout is expected to be gradual as clinicians develop competence. Furthermore, there is currently no dedicated government funding for these ADHD services within general practice, meaning costs for assessments may vary and be borne by patients.

Concerns have also been raised by some clinicians regarding the potential for over-diagnosis, over-prescribing, and the diversion of stimulant medications. Despite these concerns, the move is widely viewed as a crucial step towards improving the quality of life for many adults living with undiagnosed or untreated ADHD in New Zealand.